Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • Log out
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds

Index by author

September 1, 2022; Volume 63,Issue 9

This Month in JNM

  • You have access
    This Month in JNM
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 8A;

Discussions with Leaders

  • You have access
    A Life in Nuclear Medicine in Israel
    Ora Israel and Johannes Czernin
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1285-1287; DOI: https://doi.org/10.2967/jnumed.122.264711

The State of the Art

  • You have access
    Nuclear Medicine and Artificial Intelligence: Best Practices for Evaluation (the RELAINCE Guidelines)
    Abhinav K. Jha, Tyler J. Bradshaw, Irène Buvat, Mathieu Hatt, Prabhat KC, Chi Liu, Nancy F. Obuchowski, Babak Saboury, Piotr J. Slomka, John J. Sunderland, Richard L. Wahl, Zitong Yu, Sven Zuehlsdorff, Arman Rahmim and Ronald Boellaard
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1288-1299; DOI: https://doi.org/10.2967/jnumed.121.263239

Hot Topics

  • You have access
    Choice Is Good at Times: The Emergence of [64Cu]Cu-DOTATATE–Based Somatostatin Receptor Imaging in the Era of [68Ga]Ga-DOTATATE
    Abhishek Jha, Mayank Patel, Jorge A. Carrasquillo, Clara C. Chen, Corina Millo, Roberto Maass-Moreno, Alexander Ling, Frank I. Lin, Ronald M. Lechan, Thomas A. Hope, David Taïeb, Ali Cahid Civelek and Karel Pacak
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1300-1301; DOI: https://doi.org/10.2967/jnumed.122.264183

Continuing Education

  • You have access
    Pretargeting: A Path Forward for Radioimmunotherapy
    Sarah M. Cheal, Sebastian K. Chung, Brett A. Vaughn, Nai-Kong V. Cheung and Steven M. Larson
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1302-1315; DOI: https://doi.org/10.2967/jnumed.121.262186

Focus on Molecular Imaging

  • You have access
    Antibody Engineering for Nuclear Imaging and Radioimmunotherapy
    Cindy Rodriguez, Samantha Delaney, Samantha M. Sarrett, Outi M. Keinänen and Brian M. Zeglis
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1316-1322; DOI: https://doi.org/10.2967/jnumed.122.263861

Editorial

  • You have access
    Radionuclide Evaluation of Brain Death in the Post-McMath Era: Epilogue and Enigmata
    Lionel S. Zuckier
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1323-1325; DOI: https://doi.org/10.2967/jnumed.122.263972

Theranostics

  • Clinical

    • Targeted <strong>α</strong>-Emitter Therapy with <sup>212</sup>Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
      You have access
      Targeted α-Emitter Therapy with 212Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial
      Ebrahim S. Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason Hurt, Afshin Shafie and Rodolfo Núñez
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1326-1333; DOI: https://doi.org/10.2967/jnumed.121.263230
    • Utility of <sup>18</sup>F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
      You have access
      Utility of 18F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology
      Thomas Langbein, Hui Wang, Isabel Rauscher, Markus Kroenke, Karina Knorr, Alexander Wurzer, Kristina Schwamborn, Tobias Maurer, Thomas Horn, Bernhard Haller, Hans-Jürgen Wester and Matthias Eiber
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1334-1342; DOI: https://doi.org/10.2967/jnumed.121.263440
    • Changes in Management After <sup>18</sup>F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes
      You have access
      Changes in Management After 18F-DCFPyL PSMA PET in Patients Undergoing Postprostatectomy Radiotherapy, with Early Biochemical Response Outcomes
      Michael Ng, Mario Guerrieri, Lih Ming Wong, Kim Taubman, Tom Sutherland, Angela Benson, Graeme Byrne, Sam Koschel, Kelvin Yap, Michelle Starmans, Grace Ong, Craig Macleod, Marcus Foo and Michael Chao
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1343-1348; DOI: https://doi.org/10.2967/jnumed.121.263521
    • Radiation Protection and Occupational Exposure on <sup>68</sup>Ga-PSMA-11–Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy
      You have access
      Radiation Protection and Occupational Exposure on 68Ga-PSMA-11–Based Cerenkov Luminescence Imaging Procedures in Robot-Assisted Prostatectomy
      Pedro Fragoso Costa, Wolfgang P. Fendler, Ken Herrmann, Patrick Sandach, Hong Grafe, Maarten R. Grootendorst, Lukas Püllen, Claudia Kesch, Ulrich Krafft, Jan P. Radtke, Stephan Tschirdewahn, Boris A. Hadaschik and Christopher Darr
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1349-1356; DOI: https://doi.org/10.2967/jnumed.121.263175
  • Basic

    • Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
      You have access
      Administration Routes for SSTR-/PSMA- and FAP-Directed Theranostic Radioligands in Mice
      Jasmin M. Klose, Jasmin Wosniack, Janette Iking, Magdalena Staniszewska, Fadi Zarrad, Marija Trajkovic-Arsic, Ken Herrmann, Pedro Fragoso Costa, Katharina Lueckerath and Wolfgang P. Fendler
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1357-1363; DOI: https://doi.org/10.2967/jnumed.121.263453
    • FEATURED BASIC SCIENCE ARTICLE

      • Substitution of <span class="sc">l</span>-Tryptophan by <strong>α</strong>-Methyl-<span class="sc">l</span>-Tryptophan in <sup>177</sup>Lu-RM2 Results in <sup>177</sup>Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability
        Open Access
        Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability
        Thomas Günther, Sandra Deiser, Veronika Felber, Roswitha Beck and Hans-Jürgen Wester
        Journal of Nuclear Medicine September 1, 2022, 63 (9) 1364-1370; DOI: https://doi.org/10.2967/jnumed.121.263323

Oncology

  • Clinical

    • Prospective Phase II Trial of Prognostication by <sup>68</sup>Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
      You have access
      Prospective Phase II Trial of Prognostication by 68Ga-NOTA-AE105 uPAR PET in Patients with Neuroendocrine Neoplasms: Implications for uPAR-Targeted Therapy
      Esben Andreas Carlsen, Mathias Loft, Annika Loft, Anne Kiil Berthelsen, Seppo W. Langer, Ulrich Knigge and Andreas Kjaer
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1371-1377; DOI: https://doi.org/10.2967/jnumed.121.263177
    • <sup>18</sup>F-FDG PET/CT–Based Prognostic Survival Model After Surgery for Head and Neck Cancer
      You have access
      18F-FDG PET/CT–Based Prognostic Survival Model After Surgery for Head and Neck Cancer
      Gwenaelle Creff, Franck Jegoux, Xavier Palard, Adrien Depeursinge, Ronan Abgral, Remi Marianowski, Jean-Christophe Leclere, Thomas Eugene, Olivier Malard, Renaud De Crevoisier, Anne Devillers and Joel Castelli
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1378-1385; DOI: https://doi.org/10.2967/jnumed.121.262891
  • Translational

    • Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI
      Open Access
      Interrogating Glioma-Associated Microglia and Macrophage Dynamics Under CSF-1R Therapy with Multitracer In Vivo PET/MRI
      Claudia Foray, Cristina Barca, Alexandra Winkeler, Stefan Wagner, Sven Hermann, Michael Schäfers, Oliver M. Grauer, Bastian Zinnhardt and Andreas H. Jacobs
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1386-1393; DOI: https://doi.org/10.2967/jnumed.121.263318
  • Basic

    • <sup>68</sup>Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer
      Open Access
      68Ga-DOTA-NT-20.3 Neurotensin Receptor 1 PET Imaging as a Surrogate for Neuroendocrine Differentiation of Prostate Cancer
      Wenyu Wu, Fei Yu, Pengjun Zhang, Ting Bu, Jingjing Fu, Shuyue Ai, Qinqin You, Liang Shi, Guoqiang Shao, Feng Wang, Marina Hodolic and Hongqian Guo
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1394-1400; DOI: https://doi.org/10.2967/jnumed.121.263132
    • Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
      You have access
      Molecular Imaging of Neuroendocrine Prostate Cancer by Targeting Delta-Like Ligand 3
      Joshua A. Korsen, Teja M. Kalidindi, Samantha Khitrov, Zachary V. Samuels, Goutam Chakraborty, Julia A. Gutierrez, John T. Poirier, Charles M. Rudin, Yu Chen, Michael J. Morris, Nagavarakishore Pillarsetty and Jason S. Lewis
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1401-1407; DOI: https://doi.org/10.2967/jnumed.121.263221

Neurology

  • Basic

    • Short-Term Colony-Stimulating Factor 1 Receptor Inhibition–Induced Repopulation After Stroke Assessed by Longitudinal <sup>18</sup>F-DPA-714 PET Imaging
      Open Access
      Short-Term Colony-Stimulating Factor 1 Receptor Inhibition–Induced Repopulation After Stroke Assessed by Longitudinal 18F-DPA-714 PET Imaging
      Cristina Barca, Amanda J. Kiliaan, Lydia Wachsmuth, Claudia Foray, Sven Hermann, Cornelius Faber, Michael Schäfers, Maximilian Wiesmann, Bastian Zinnhardt and Andreas H. Jacobs
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1408-1414; DOI: https://doi.org/10.2967/jnumed.121.263004

Cardiovascular

  • Clinical

    • FEATURED ARTICLE OF THE MONTH

      • Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome
        You have access
        Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome
        Johanna Diekmann, Tobias Koenig, James T. Thackeray, Thorsten Derlin, Christoph Czerner, Jonas Neuser, Tobias L. Ross, Andreas Schäfer, Jochen Tillmanns, Johann Bauersachs and Frank M. Bengel
        Journal of Nuclear Medicine September 1, 2022, 63 (9) 1415-1423; DOI: https://doi.org/10.2967/jnumed.121.263555

AI/Advanced Image Analysis

  • The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in <sup>18</sup>F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
    You have access
    The Impact of Semiautomatic Segmentation Methods on Metabolic Tumor Volume, Intensity, and Dissemination Radiomics in 18F-FDG PET Scans of Patients with Classical Hodgkin Lymphoma
    Julia Driessen, Gerben J.C. Zwezerijnen, Heiko Schöder, Esther E.E. Drees, Marie José Kersten, Alison J. Moskowitz, Craig H. Moskowitz, Jakoba J. Eertink, Henrica C.W. de Vet, Otto S. Hoekstra, Josée M. Zijlstra and Ronald Boellaard
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1424-1430; DOI: https://doi.org/10.2967/jnumed.121.263067

Endocrinology

  • Clinical

    • Invited Perspective

      • You have access
        18F-FDG Uptake in Brown Adipose Tissue After Exposure to the Cold: From Possible Pitfall in Early PET Scans to Metabolic Biomarker
        Paola A. Erba, Andrea Natali, H. William Strauss and Giuliano Mariani
        Journal of Nuclear Medicine September 1, 2022, 63 (9) 1431-1432; DOI: https://doi.org/10.2967/jnumed.122.264188
      • Brown Adipose Tissue: A Protective Mechanism Against “Preprediabetes”?
        You have access
        Brown Adipose Tissue: A Protective Mechanism Against “Preprediabetes”?
        John P. Crandall, Tyler J. Fraum and Richard L. Wahl
        Journal of Nuclear Medicine September 1, 2022, 63 (9) 1433-1440; DOI: https://doi.org/10.2967/jnumed.121.263357

Radiobiology/Dosimetry

  • Special Contribution

    • MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
      Open Access
      MIRD Pamphlet No. 27: MIRDcell V3, a Revised Software Tool for Multicellular Dosimetry and Bioeffect Modeling
      Sumudu Katugampola, Jianchao Wang, Alex Rosen and Roger W. Howell
      Journal of Nuclear Medicine September 1, 2022, 63 (9) 1441-1449; DOI: https://doi.org/10.2967/jnumed.121.263253

The Illustrated Post

  • You have access
    Antibody-Guided Molecular Imaging of Aspergillus Lung Infections in Leukemia Patients
    Johannes Schwenck, Andreas Maurer, Nicolas Beziere, Francesco Fiz, Frederic Boschetti, Susanne Geistlich, Dominik Seyfried, Matthias Gunzer, Gerald Reischl, Jöri Wehrmüller, Walter Ehrlichmann, Marius Horger, Sergios Gatidis, Genna Davies, Wichard Vogel, Christian la Fougère, Bernd Pichler and Christopher Thornton
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1450-1451; DOI: https://doi.org/10.2967/jnumed.121.263251

Letters to the Editor

  • Open Access
    Brain Metabolic PET Findings on the Long-Term Effects of COVID-19
    Eric Guedj and Tatiana Horowitz
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 1452-1453; DOI: https://doi.org/10.2967/jnumed.122.264179

SNMMI Newsline

  • You have access
    SNMMI Newsline
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 11N-22N;
  • You have access
    SNMMI Honors Contributors, Recognizes Scientific Excellence at 2022 Annual Meeting
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 11N-13N;
  • You have access
    Full Steam Ahead for Nuclear Medicine Therapy
    Munir Ghesani
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 14N;
  • You have access
    NewsBriefs
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 16N-18N;
  • You have access
    From the Literature
    Journal of Nuclear Medicine September 1, 2022, 63 (9) 19N-22N;
Back to top
PreviousNext

In this issue

Journal of Nuclear Medicine: 63 (9)
Journal of Nuclear Medicine
Vol. 63, Issue 9
September 1, 2022
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Complete Issue (PDF)

Issue highlights

  • Cardiac Fibroblast Activation in Patients Early After Acute Myocardial Infarction: Integration with MR Tissue Characterization and Subsequent Functional Outcome
  • Substitution of l-Tryptophan by α-Methyl-l-Tryptophan in 177Lu-RM2 Results in 177Lu-AMTG, a High-Affinity Gastrin-Releasing Peptide Receptor Ligand with Improved In Vivo Stability
Sign up for alerts

Jump to

  • This Month in JNM
  • Discussions with Leaders
  • The State of the Art
  • Hot Topics
  • Continuing Education
  • Focus on Molecular Imaging
  • Editorial
  • Theranostics
    • Clinical
    • Basic
      • FEATURED BASIC SCIENCE ARTICLE
  • Oncology
    • Clinical
    • Translational
    • Basic
  • Neurology
    • Basic
  • Cardiovascular
    • Clinical
      • FEATURED ARTICLE OF THE MONTH
  • AI/Advanced Image Analysis
  • Endocrinology
    • Clinical
      • Invited Perspective
  • Radiobiology/Dosimetry
    • Special Contribution
  • The Illustrated Post
  • Letters to the Editor
  • SNMMI Newsline
  • Most Cited
  • Most Read
Loading
  • MIRD Pamphlet No. 28, Part 1: MIRDcalc—A Software Tool for Medical Internal Radiation Dosimetry
  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Prediction of 177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
  • Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy
  • High-Temporal-Resolution Lung Kinetic Modeling Using Total-Body Dynamic PET with Time-Delay and Dispersion Corrections
More...
SNMMI

© 2025 SNMMI

Powered by HighWire